• 1
    Häussler B, Gothe H, Göl D, et al. Epidemiology, treatment and costs of osteoporosis in Germany—the boneEVA study. Osteoporos Int 2007;18:7784.
  • 2
    IPSOS-SRL. How fragile is her future? Osteoporosis Research in Partnership with International Osteoporosis Foundation (IOF). 2000.
  • 3
    Black DM, Delmas PD, Eastell R, et al. HORIZON pivotal fracture trial: once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2000;356:180922.
  • 4
    Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture intervention trial research group. Lancet 1996;348:153541.
  • 5
    Cummings SR, Black DM, Thompson DE, et al. for the Fracture Interventioin Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:207782.
  • 6
    Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:7928.
  • 7
    Harris ST, Watts NB, Genant HK, et al. for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:134452.
  • 8
    McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:33340.
  • 9
    Reginster J, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fracture in women with established postmenopausal osteoporosis. Vertebral Efficacy in Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:8391.
  • 10
    Fleurence RL, Iglesias CP, Johnson JM The cost-effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 2007;25:91333.
  • 11
    Aursnes I, Storvik G, Gasemyr J, Natvig B. A Bayesian analysis of bisphosphonates effects and cost-effectiveness in post-menopausal osteoporosis. Pharmacoepidemiol Drug Saf 2000;9:5019.
  • 12
    Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 2005;96:38796.
  • 13
    Coyle D, Cranney A, Lee KM, et al. Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 2001;19:56575.
  • 14
    Francis RM, Anderson FH, Torgerson DJ. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 1995;34:116771.
  • 15
    Grima DT, Burge RT, Becker DL, Tosteson ANA. Short-term cost-effectiveness of bisphosphonates therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 2002; 27:44855.
  • 16
    Hart WM, Rubio TC, Burrell A. Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate [in Spanish. Rev Esp Enferm Metab Oseas 2002;11:97104.
  • 17
    Iglesias CP, Torgerson DJ, Bearne A, Bose U. The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 2002;95:30511.
  • 18
    Johnell O, Jönsson B, Jönsson L, Black D. Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003;21:30514.
  • 19
    Kanis JA, Borgstrom F, Johnell O, Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004;15:86271.
  • 20
    Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6:1146.
  • 21
    Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006;99:12331.
  • 22
    Rodriguez Escolar C, Fidalgo García ML, Rubio Cebrián S. A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture [in Spanish. Aten Primaria 1999;24:3906.
  • 23
    Rosner AJ, Grima DT, Torrance GW, et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998;14:55973.
  • 24
    Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int 2005;16:188393.
  • 25
    Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1160.
  • 26
    Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:2534.
  • 27
    Garrison LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR real-world task force report. Value Health 2007;10:32635.
  • 28
    Grima DT, Papaioannou A, Thompson MF, et al. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int 2008;19:68797.
  • 29
    Barbieri M, Drummond M, Wilke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005;8:1023.
  • 30
    Drummond MF, Pang F Transferability of economic evaluation results. In: DrummondMF, McGuireA, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press, 2001.
  • 31
    Tosteson ANA, Jönsson B, Grima DT, et al. Challenges for model-based economic evaluation of post-menopausal osteoporosis interventions. Osteoporos Int 2001;12:84957.
  • 32
    Zethraeus N, Börgstrom F, Störm O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 2007;18:923.
  • 33
    Brecht JG, Kruse HP, et al. Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 2003;22:93105.
  • 34
    Burge RT, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporotic fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:46575.
  • 35
    Burge RT, Worley D, Johansen A, et al. The cost of osteoporotic fractures in the UK: projections for 2000–2020. J Med Econ 2001;4:5162.
  • 36
    King AB, Saag KG, Burge RT, et al. Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment. Osteoporos Int 2005;16:154557.
  • 37
    Borgström F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006;17:9961007.
  • 38
    Evidenzbasierte Konsensus-Leitlinie zur Osteoporose. Evidenzbasierte Konsensus-Leitlinie zur Osteoporose: Prophylaxe, Diagnostik und Therapie—bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr. Available from:[Accessed October 5, 2009].
  • 39
    Felsenberg D, Wieland E, Hammermeister C, et al. Prävalenz der vertebralen Wirbelkörperdeformationen bei Frauen and Männern in Deutschland. Med Klin 1998;93:314.
  • 40
    Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:103346.
  • 41
    Federal Statistical Office (Statistics Bundesamt). 2005. Health component of Consumer Price Index. Available from: [Accessed January 20, 2009.
  • 42
    Black DM, Palermo L, Grima DT. Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value Health 2006;9:548.
  • 43
    Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:46873.
  • 44
    Johnell O, Kanis JA, Odén A, Sernbo I. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:3842.
  • 45
    Tosteson ANA, Gottlieb DJ, Radley DC, et al. Excess mortality following hip fracture: the role of underlying health states. Osteoporos Int 2007;18:146372.
  • 46
    Delmas PD, Silverman SL, Watts NB Bisphosphonate therapy and hip fractures within the risedronate and alendronate (REAL) cohort study: a comparison to patients with minimal bisphosphonate exposure. J Bone Miner Res 2007;22(Suppl.):S328.
  • 47
    Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:62135.
  • 48
    Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004;15:206.
  • 49
    LAUER-FISCHER GmbH. Lauer-Taxe Online, available by subscription. Available from:[Accessed January 20, 2009.
  • 50
    Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:51321.
  • 51
    Bartl R, Goette S, Hadji P, Hammerschmidt T. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment [article in German. Dtsch Med Wochenschr 2006;131:125762.
  • 52
    Wildner M, Clarke DE. Hip fracture incidence in east and West Germany: reassessment 10 years after unification. Osteoporos Int 2001;12:1369.
  • 53
    US Census Bureau. Selected age groups for the population by race and Hispanic origin in the United States. Available from:[Accessed February 2, 2009.
  • 54
    National Osteoporosis Foundation. Fast facts on osteoporosis. Available from:[Accessed February 2, 2009.
  • 55
    McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26:73344.
  • 56
    Brecht JG, Kruse HP, Möhrke W, et al. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 2004;24:110.